월경전 증후군 치료 시장 규모, 점유율 및 성장 분석 : 제품 유형별, 약제 유형별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Premenstrual Syndrome Treatment Market size was valued at USD 1.44 Billion in 2024 and is poised to grow from USD 1.49 Billion in 2025 to USD 1.95 Billion by 2033, growing at a CAGR of 3.42% in the forecast period (2026-2033).

The global premenstrual syndrome (PMS) treatment market is experiencing growth driven by heightened awareness of PMS and its impact on women's health, alongside an increasing demand for effective treatment options. There is a significant shift toward non-hormonal and integrative therapies, mirroring broader healthcare trends toward personalized, non-invasive treatments. Major pharmaceutical and healthcare companies are actively investing in research and development to introduce innovative therapies. However, the market faces challenges, including regulatory hurdles that hinder treatment approval and accessibility, along with inconsistent treatment protocols leading to varied patient outcomes. As digital health solutions, like mobile apps for PMS management, gain traction, concerns regarding data privacy and security become paramount. Ensuring robust data protection will be critical as the industry evolves alongside technological integration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Premenstrual Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Premenstrual Syndrome Treatment Market Segments Analysis

The global premenstrual syndrome treatment market is segmented into product, drug, distribution channel, and region. by product, the market is classified into Prescription and Over-the-Counter (OTC). Depending on the drug, it is divided into Analgesics, Antidepressants, and Oral Contraceptives & Ovarian Suppression Agents. According to distribution channel, the market is categorized into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Premenstrual Syndrome Treatment Market

The growing awareness surrounding premenstrual syndrome (PMS) and its symptoms has significantly fueled the demand for treatment options in the market. Public awareness campaigns and educational initiatives play a crucial role in enhancing understanding among women regarding PMS, ultimately encouraging them to seek medical advice. Organizations dedicated to this cause, like the International Association for Premenstrual Disorders (IAPMD), actively promote awareness, leading women to healthcare providers. This increased diagnosis of PMS paves the way for a higher demand for various treatment options, including oral contraceptives, thus expanding the scope of the global premenstrual syndrome treatment market.

Restraints in the Global Premenstrual Syndrome Treatment Market

The Global Premenstrual Syndrome Treatment market faces significant challenges due to the stigma surrounding mental health issues associated with PMS, which often leads to underreporting of symptoms. In various cultures, discussing PMS and its related symptoms among women can be considered taboo, resulting in a reluctance to seek treatment or openly address the condition. This cultural reluctance diminishes the demand for effective therapies, such as antidepressants or hormonal treatments, thereby hindering the overall growth of the market. As a result, increased awareness and acceptance are necessary to help overcome these obstacles and expand treatment options for those affected.

Market Trends of the Global Premenstrual Syndrome Treatment Market

The Global Premenstrual Syndrome (PMS) Treatment market is witnessing a notable shift towards natural and holistic solutions, as consumers increasingly prefer herbal and plant-based remedies over traditional pharmaceuticals. This trend reflects a rising awareness of wellness and a desire for drug-free alternatives to alleviate PMS symptoms like cramping and mood swings. The incorporation of natural ingredients such as vitamin B6, calcium, and magnesium not only appeals to consumers seeking sustainable options but also fosters a growing market for innovative herbal treatments. Businesses tapping into this demand are thriving, contributing to a transformative landscape where health and wellness priorities shape PMS management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Premenstrual Syndrome Treatment Market Size by Product & CAGR (2026-2033)

• Market Overview
• Prescription
• Over-the-Counter (OTC)

Global Premenstrual Syndrome Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Analgesics
• Antidepressants
• Oral Contraceptives & Ovarian Suppression Agents

Global Premenstrual Syndrome Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Drug Stores & Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Premenstrual Syndrome Treatment Market Size & CAGR (2026-2033)

• North America (Product, Drug Type, Distribution Channel)
  • US
  • Canada
• Europe (Product, Drug Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Drug Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Drug Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Drug Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BASF SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SHIONOGI & Co. Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asarina Pharma AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vistagen Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Herbalife International of America, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Nature's Bounty Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations